Canetti Michal, Barda Noam, Lustig Yaniv, Weiss-Ottolenghi Yael, Indenbaum Victoria, Peretz Yovel, Zuckerman Neta, Asraf Keren, Amit Sharon, Kreiss Yitshak, Regev-Yochay Gili
The Sheba Pandemic Preparedness Research Institute, Sheba Medical Center, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
The Sheba Pandemic Preparedness Research Institute, Sheba Medical Center, Ramat Gan, Israel.; ARC Innovation Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel; Epidemiology, Biostatistics, and Community Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Vaccine. 2024 Dec 2;42(26):126308. doi: 10.1016/j.vaccine.2024.126308. Epub 2024 Sep 9.
Correlates of protection for recent emerging SARS-CoV-2 variants have not been determined. In this test-negative case-control study, we report lower odds of infection with XBB variants among those boosted during the last six months. Additionally, we demonstrate that XBB-specific neutralizing antibodies are independent correlates of protection.
针对近期出现的新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的保护相关因素尚未确定。在这项检测阴性的病例对照研究中，我们报告称，在过去六个月内接种过加强针的人群中，感染XBB变体的几率较低。此外，我们证明XBB特异性中和抗体是独立的保护相关因素。
